Meeting
2014 Gastrointestinal Cancers Symposium
Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer.
Authors
Michael Sangmin Lee
The University of Texas MD Anderson Cancer Center, Houston, TX
Michael Sangmin Lee , Christopher Hanyoung Lieu , Michael J. Overman , Cathy Eng , Jeffrey Morris , Zhi-Qin Jiang , Maria Morelli , John Heymach , Hai T. Tran , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 452)
DOI
10.1200/jco.2014.32.3_suppl.452
Abstract #
452
Poster Bd #
B15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
First Author: Stefania Napolitano
Poster
2017 ASCO Annual Meeting
Emergence of KRAS mutations and acquisition of resistance to EGFR blockade.
First Author: Takeshi Yamada
Poster
2015 Gastrointestinal Cancers Symposium
EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR).
First Author: Yu Sunakawa